TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mother Child interaction Quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Colorectal lesion detection performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular corrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anxiety, depression and stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Testosterone Suppression of Participants as Assessed by Testosterone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Length of Leukocyte telomere
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Left Ventricular Mass Index (LVMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-leeds assessment of neuropathic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anxiety levels as measured by Beck's Anxiety Inventory, Youth Version
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to the first Atopic Dermatitis (AD) flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious and non-serious treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Major Congenital Malformations (MCMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and Tolerability as Assessed by Adverse events (AEs) and Serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Magnitude of translational corrections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in FSIQ WPPSI-IV Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in FSIQ WISC-V Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cashew full tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality from gastrointestinal cancers
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of gastrointestinal cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection of gastrointestinal cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: length of calf muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants with One or More Solicited Local Reactogenicity Signs and Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with One or More Solicited Systemic Reactogenicity Signs and Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in muscle protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: avoidance rate of grade III-IV acute GVHD at day +100
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of infants who receive EID testing by age 6 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of HPV L1 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV16/18 virion detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prosthesis success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Biochemical hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absence of serious adverse events (SAE) and of serious adverse device effects (SADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of critical change in patient's blood pressure (mm Hg) during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absence of critical change in patient's heart rate (bpm) during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Suicide Visual Analog Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in WSRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with clinically significant changes from baseline in Physical Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure Pain Measurement with Algometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pittsburgh Sleep Quality Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Schober Flexibility Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The finger-to-floor distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tampa Kinesiophobia Fatigue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Oswestry Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 30-Day Postoperative Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of participants with reactogenicity events for 7 days after Doses 1, 2, and 3
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with adverse events (AEs) from Dose 1 to 28 days after Dose 3
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with medically attended AEs (MAAEs) from Dose 1 to 6 months after Dose 3
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with newly diagnosed chronic medical conditions (NDCMCs) from Dose 1 to 6 months after Dose 3
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Satisfaction With Wound Appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positivity rate of 68Ga-FAPi PET/CT and 18F-FDG PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of at least 5% of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference between SpO2 and SaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cocaine Demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure changes post-epileptic seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pelvic floor muscles force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in basal ganglia glutamate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structure-function coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of NACE
Endpoint domain: Adverse events/effects
Primary endpoint: Body skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Pancreatic Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fetal Pancreatic Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of emotional abuse of older people
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of physical abuse of older people
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of sexual abuse of older people
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of financial abuse of older people
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of neglect of older people
Endpoint domain: Adverse events/effects
Primary endpoint: Infection caused by multidrug-resistant organism
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of effective jugular access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of effective same-day discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of major cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Responding Against HBV Vaccine Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Children's Sleep Habits Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Appropriateness
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Serum levels of CTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inclinometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Poor prognosis in patients with pancreatic cancer
Endpoint domain: Mortality/survival
Primary endpoint: Inter-observer reliability of tooth color selection methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic trough voriconazole concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in facial microbiota profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of BioPB-01 administration
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of honey as a disinfectant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number and grad of embryos exposed to oxygen concentration 2%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instructional Material Motivation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in fibroblast growth factor-23
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall Symptom and Sign Score Improvement Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported Dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients with sodium-related conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: severe postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Vascular events and all-causes death
Endpoint domain: Mortality/survival
Primary endpoint: Risk factor control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in glutamate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective implementation rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: F1 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants experiencing treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Peak oxygen uptake (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic Pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure-evoked Pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma amyloid beta levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma Ab42/40 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-rated fatigue severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prenatal attachment scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tilburg pregnancy distress scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Insomnia Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Histopathological grading in breast cancer patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Behavioral Inhibition/ Behavioral Activation Scale (BIS/BAS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Achieving ACR 30 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acceptability of storylines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of interactive components
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Experience a Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) of Ziftomenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single-Pool Standardized Dialysis Adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Blood Chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Complete Blood Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in Iron Studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eccentron maximal muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local muscle hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of HEC585 and Pirfenidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of HEC585 and Pirfenidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of HEC585 and Nintedanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of HEC585 and Nintedanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of first spontaneous breathing trial tolerated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Skin burn rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Postoperative Fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of treatment completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cytokine changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerance Break Completion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment plan acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: q max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for hysterectomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of grade 3 or greater neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in parent-rated child psychopathology symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in child self-reported psychopathology symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in child emotional-behavioural problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Zarit Caregiving Burden Interview
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Center for Epidemiological Studies Depression Scale (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Self-Rated Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Neuropsychiatric Inventory Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Deformability of erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aggregation of erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: episiotomy skill performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Oncological status according to tumor, node, metastasis (TNM) classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of EORTC QLQ-C30 Quality of Life Scale and QLQ-BR23 Module score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Memorial Symptom Assessment Scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Multidimensional Scale of Perceived Social Support score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change of Beck Anxiety Inventory scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebrospinal fluid density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gastroesophageal Reflux Disease Questionnaire (GERDQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reflux Symptom Index (RSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Global Symptom Severity Questionnaire (GSS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of people with foot drop accepting the invitation to participate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Degree of satisfaction of cosmetic appearance of the thyroidectomy scar
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Copeptin plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vaginal local irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in vaginal moisturizing effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in sexual intimacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in VAS score for vaginal itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Identification of inner ear congenital and acquired abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased Days of MA Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Left ventricular outflow tract pressure gradient (Valsalva LVOT-G)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SNP effect in FOXP3 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IL-10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical presentation in adult patients with ITP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forgotten Joint Score (FJS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Goal Participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Problematic Experience of Therapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Early sensory relearning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with Grade 3 to 4 treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 129Xe MRI barrier uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Photopic Monocular logMAR Best Corrected Distance Visual Acuity (BCDVA) at 4 Meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Photopic Monocular logMAR Distance Corrected Near Visual Acuity (DCNVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of 1st Operative Eyes With Secondary Surgical Interventions (SSIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal Weight Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Fat Accretion Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identify Changes in Dietary Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients' pain score after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with 1827 Nodule Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants with Weak Vaccine Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of Work-Related Musculoskeletal Disorders (WMSDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline 3-dimensional left ventricular ejection fraction (3D-LVEF) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes